Autolus(AUTL) - 2020 Q2 - Earnings Call Presentation

Clinical Program Updates - AUTO1 pivotal study in adult ALL was initiated in Q2 2020 as planned, with full data expected by the end of 2021[8, 9, 19] - AUTO3 continues to enroll patients in DLBCL study, with outpatient cohort initiated and next data update at ESMO in September 2020 and Q4 2020[8, 10] - AUTO4 Phase 1 clinical trial in TRBC1+ Peripheral TCL experienced enrollment pause due to COVID-19, with first data expected in H1 2021[8] - AUTO1NG in pALL and AUTO8 in multiple myeloma are on track to start Phase 1 in H2 2020[8] - AUTO5, AUTO6NG, and AUTO7 are expected to enter clinical development in 2021[8, 12] Corporate Highlights - Dr Jay T Backstrom was appointed to the Board of Directors[13] - Dr Nushmia Khokhar was promoted to Senior Vice President, Clinical Development[13] - Manufacturing capacity was extended at the Cell and Gene Therapy Catapult to secure initial commercial launch capability[13] Financial Overview - Cash balance as of June 30, 2020, was $212 million[33, 37] - Total operating expenses, net, for Q2 2020 were $39.5 million, compared to $37.2 million for Q2 2019[33] - Net loss for Q2 2020 was $32 million, compared to $28.5 million for Q2 2019[33]